E. Rodriguez

Substance P Antagonism Prevents Chemotherapy-Induced Cardiotoxicity

Ashiq Legi, E. Rodriguez, T. K. Eckols, 2021, Cancers.

Substance P—Friend or Foe

E. Rodriguez, P. Robinson, M. Muñoz, 2022, Journal of clinical medicine.

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

M. Suarez‐Almazor, H. Tawbi, S. Patel, 2022, Nature Communications.

Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis

Guangsheng Pei, E. Rodriguez, P. Robinson, 2021, Cancers.

Genetic and Small-Molecule Modulation of Stat3 in a Mouse Model of Crohn’s Disease

D. Tweardy, E. Rodriguez, P. Robinson, 2022, Journal of clinical medicine.

Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871

Zhongming Zhao, Guangsheng Pei, E. Rodriguez, 2021, Cancers.

Therapeutic Potential of a Small-Molecule STAT3 Inhibitor in a Mouse Model of Colitis

D. Tweardy, E. Rodriguez, P. Robinson, 2023, Cancers.